Completed PHASE2 INTERVENTIONAL 2-arm NCT04701502

Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

Sponsor: Catalysis SL

Conditions Antiseptic Covid19 Immune System Immunomodulator Respiratory Disease Supportive Care

Interventions Asbrip Standard Care Viusid

Updated 5 times since 2021 Last updated: Oct 20, 2021 Started: Nov 9, 2020 Primary completion: Feb 15, 2021 Completion: Feb 15, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Antiseptic and Covid19, this trial is completed. The trial is conducted by Catalysis SL and has accumulated 5 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2021 — Nov 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE2

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catalysis SL

Data source: Catalysis SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Plovdiv, Bulgaria